CoChat

Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre

Baldi, Bruno Guedes, Samano, Marcos Naoyuki, Campos, Silvia Vidal, de Oliveira, Martina Rodrigues, Junior, José Eduardo Afonso, Carraro, Rafael Medeiros, Teixeira, Ricardo Henrique Oliveira Braga, Minguini, Isabela Pasqualini, Burlina, Roni, Pato, Eduardo Zinoni Silva, Carvalho, Carlos Roberto Ribeiro, Costa, André Nathan · 2017 · Lung

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Introduction Lung transplantation (LT) is the standard of care for patients with advanced lung diseases, including lymphangioleiomyomatosis (LAM). LAM accounts for only 1% of all LTs performed in the international registry. As a result, the global experience, including the use of mechanistic target of rapamycin (mTOR) inhibitors before and after LT in LAM, is still limited. Methods We conducted a retrospective review of all LAM patients who underwent LT at our centre between 2003 and 2016. Pre- and post-transplant data were assessed. Results Eleven women with LAM underwent LT, representing 3.3% of all procedures. Ten (91%) patients underwent double-LT. The mean age at diagnosis was 39 ± 6 years and the mean FEV 1 before LT was 28 ± 14%. Only one patient underwent pleurodesis for recurrent pneumothorax. Pulmonary hypertension was confirmed in 3 (27%) patients. Four (36%) patients received sirolimus preoperatively; three of them received it until the day of LT, and there was no occurrence of bronchial anastomotic dehiscence after the procedure. Four patients (36%) received mTOR inhibitors post-transplant. The median follow-up from LT was 44 months. There were 3 deaths (27%) during the study and survival probabilities at 1, 3, and 5 years after LT were, 90, 90, and 77%, respectively. Conclusions This data reinforces the role of LT for LAM patients with end-stage disease. The use of sirolimus seems to be safe before LT and the occurrence of complications after LT, including those…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00408-017-0045-y

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

See all 16

Metadata

Authors
Baldi, B. G., Samano, M. N., Campos, S. V., de Oliveira, M. R., Junior, J. E. A., Carraro, R. M., Teixeira, R. H. O. B., Minguini, I. P., Burlina, R., Pato, E. Z. S., Carvalho, C. R. R., & Costa, A. N.
Affiliations
Universidade de São Paulo (BR)
Corresponding author
Baldi, Bruno Guedes
Venue
Lung
Published
2017-08-19
Volume
195
Issue
6
Pages
699-705
ISSN
  • 0341-2040 (ISSN-L)
  • 1432-1750
OpenAlex
W2745676588
Cited by
16
References
35
Citations by year
2026: 1 · 2025: 2 · 2023: 2 · 2022: 3 · 2021: 6 · 2019: 1 · 2018: 1
FWCI
0.56
Type
journal article
Language
en
Open access
closed
Locations
  • Lung (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
lung transplantation, lymphangioleiomyomatosis, rapamycin, mTOR inhibitors, pulmonary hypertension, recurrent pneumothorax, end-stage lung disease
MeSH terms
Everolimus, Walk Test, Adult, Brazil, Female, Humans, Immunosuppressive Agents, Lung Neoplasms, Middle Aged, Retrospective Studies, Survival Rate, Lung Transplantation, Treatment Outcome, Lymphangioleiomyomatosis, Sirolimus, TOR Serine-Threonine Kinases, Tertiary Care Centers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre. https://app.cochat.ai/papers/10.1007/s00408-017-0045-y
The paper
Baldi, B. G., Samano, M. N., Campos, S. V., de Oliveira, M. R., Junior, J. E. A., Carraro, R. M., Teixeira, R. H. O. B., Minguini, I. P., Burlina, R., Pato, E. Z. S., Carvalho, C. R. R., & Costa, A. N. (2017). Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre. Lung. https://doi.org/10.1007/s00408-017-0045-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.